AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01326806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together
Description: The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
Study NCT01326806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control on Hygiene & Nutrition
Description: The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
Study NCT04505150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption
Description: Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
Study NCT00516984 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No-touch control condition applied while subject was at a 50-degree head-up tilt.
Study NCT04665804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation
Description: Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
Study NCT04665804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine and Chondroitin sulfate supplementation
Description: Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
Study NCT04665804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise training
Description: Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval
Study NCT04665804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: 2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension
Study NCT04665804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy + Heating
Description: Interferential Current therapy (2P), in combination with heating pad for 20 minutes
Study NCT04665804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
Study NCT00516984 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
Study NCT01890265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Solution for infusion
Study NCT01890265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamrevlumab
Description: Solution for infusion
Study NCT01890265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion
Study NCT01890265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study: Pirfenidone
Description: Pirfenidone concomitant therapy will not be provided by the Sponsor.
Study NCT01890265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sub-Study: Pirfenidone
Description: Pirfenidone concomitant therapy will not be provided by the Sponsor.
Study NCT01890265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study: Nintedanib
Description: Nintedanib concomitant therapy will not be provided by the Sponsor.
Study NCT01890265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sub-Study: Nintedanib
Description: Nintedanib concomitant therapy will not be provided by the Sponsor.
Study NCT04054336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibit AAT
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
Study NCT04054336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: classical AAT
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
Study NCT00516984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMT
Description: Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
Study NCT00863980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micardis (Telmisartan)
Description: 40-80 mg/day oral administration
Study NCT00863980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blopress (Candesartan)
Description: 8-12 mg/day oral administration
Study NCT00460837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bowel preparation: senna & gastrofin versus picolax (standard)
Description: The intervention is a bowel cleansing procedure
Study NCT04054336 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
Study NCT00554138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 dd for 7-10 days
Study NCT00554138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 1 dd 20 mg for 7-10 days
Study NCT04271475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Participants will receive Macitentan film-coated tablets orally od.
Study NCT04271475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive matching placebo tablets orally od.
Study NCT03091088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking at an intense pace
Description: Participants walk 6 kilometers in 1 hour at least 3 times per week
Study NCT03091088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteoporosis specific-oriented training
Description: 1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
Study NCT02417896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
Study NCT03956329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardised Digital Intervention
Description: Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Study NCT03956329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Digital Intervention
Description: Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
Study NCT02409758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy
Description: Voice therapy applied during 6 weeks.
Study NCT02409758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice therapy
Description: Voice therapy applied during 6 weeks.
Study NCT03181841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: double-blind oral intake of single doses of the aforementioned drug or placebo
Study NCT01718548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cordyceps Sinensis (CS) and Lingzhi
Study NCT01718548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tea and Flour
Description: Placebo
Study NCT01667250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GammaCore Active Device
Study NCT01667250 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GammaCore Active Device
Study NCT01667250 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GammaCore Sham Device
Study NCT02320864 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee replacement surgery
Description: The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
Study NCT02131662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study NCT02131662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study NCT00988065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo run-in dose
Description: Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
Study NCT00988065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo run-in dose
Description: Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
Study NCT02131662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study NCT02131662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study NCT02131662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study NCT02294032 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive Agents
Description: standard of care for patients post-transplant
Study NCT03961802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sessions of shoulder rehabilitation
Description: 3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
Study NCT04196725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Description: Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging
Study NCT04196725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle treatment
Description: Two weeks rehabilitation programme focusing on physical activity
Study NCT00777348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination DSCG and Reproterol
Description: 1:
Study NCT00777348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination DSCG and Reproterol
Description: 1:
Study NCT00777348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination DSCG and Reproterol
Description: 1:
Study NCT01478022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide Dinitrate 10 mgx2, daily, capsules
Study NCT01478022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg daily, capsules
Study NCT01478022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Isosorbide Dinitrate combination
Description: Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
Study NCT02670473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A (test)
Description: contact lens
Study NCT01948479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimised instant offloading insole
Study NCT01948479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimised instant offloading insole
Study NCT00196209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: catheter ablation to treat persistent atrial fibrillation
Study NCT00196209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: external electric cardioversion
Description: external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
Study NCT02619747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Sodium Alginate Oral Suspension sachet
Study NCT02619747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compound Sodium Alginate Oral Suspension sachet
Study NCT02619747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo
Study NCT02619747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Study NCT02057926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The effect of tetracycline in degradation and permeability of collagen membranes.
Study NCT02909088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam 50mg
Study NCT02909088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam 100mg
Study NCT02434211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and focus group
Study NCT00672230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein supplement
Description: Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
Study NCT01521598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL11197
Description: SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
Study NCT01521598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo. Patients will be randomized the placebo.
Study NCT03069066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold. Absorb GT1 (Abbott)
Study NCT01451749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenwu Capsule
Description: 1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months.
Study NCT01451749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months.
Study NCT04500457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based Treatment for Perfectionism (ETP)
Description: Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
Study NCT05006105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seven-day ECG Holter
Description: Participants receive a seven-day ECG Holter after hospital discharge.
Study NCT05006105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 24-hour blood pressure monitor
Description: Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
Study NCT05006105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: vision of mHealth
Description: Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
Study NCT05006105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: user experience & feeling of safety
Description: Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
Study NCT05006105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertable loop recorder
Description: Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
Study NCT03436498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart SAR341402
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT03436498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT00988065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
Study NCT00988065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg
Description: Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
Study NCT00988065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
Study NCT01882075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open loop
Study NCT01882075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Study NCT00878514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Alprazolam 1 mg tablet
Study NCT00878514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax
Description: Xanax 1 mg tablet
Study NCT00390221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection
Study NCT05496842 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multimodal pulmonary rehabilitation
Description: The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
Study NCT01671267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Study NCT01671267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic
Study NCT03300492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NK-DLI
Description: Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg.
Study NCT01336543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy following concurrent Chemoradiotherapy
Description: 1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles